Search
Seladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar works to block bile acid synthesis.[A264234]
Libivirumab
go.drugbank.com/drugs/DB17748ExperimentalIt is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Categories: Preparations With No Effect on Uric Acid MetabolismStiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. … [A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Cisapride
go.drugbank.com/drugs/DB00604ApprovedWithdrawnIn many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. … The FDA issued a warning letter regarding this risk to health care professionals and patients.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSimvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigationalThe clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America … were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.
Synonyms: 2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-oneMixtures: EZETIMIBE E SIMVASTATINA DOC GENERICI, EZETIMIBE E SIMVASTATINA DOC GENERICIDihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedTo know more about this mixture, please visit [DB01049] … This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine.[T195] Both compounds are hydrogenated ergot derivatives.
Navepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigational[L56058,A275435] Navepegritide is a prodrug of active C-type natriuretic peptide (CNP) consisting of a CNP moiety transiently conjugated to two methoxy polyethylene glycol (mPEG) moieties via a proprietary … [L56058] Developed to address the clinical limitations of daily therapies, the pegylated nature of navepegritide allows for once-weekly dosing while providing sustained systemic exposure to CNP, which
Lincomycin
go.drugbank.com/drugs/DB01627ApprovedInvestigationalVet approved[A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains
Pirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalAlthough the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK … [A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors such as pirtobrutinib.